Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
20.59
+0.86 (4.36%)
At close: Jun 6, 2025, 4:00 PM
20.75
+0.16 (0.78%)
After-hours: Jun 6, 2025, 7:53 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
15.29B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SMMT News
- 18 hours ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 days ago - Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - Business Wire
- 4 days ago - Summit Therapeutics: Market Overreaction Creates Opportunity - Seeking Alpha
- 5 days ago - Is SMMT Stock A Buy After Its Recent Plunge? - Forbes
- 7 days ago - Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release - Seeking Alpha
- 8 days ago - Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down. - Barrons
- 8 days ago - Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint - Benzinga
- 8 days ago - Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study - Business Wire